Compare Charles River Laboratories Intl. Inc (CRL) vs ImmunityBio Inc. Common Stock (IBRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs ImmunityBio Inc. Common Stock — how do they compare? Charles River Laboratories Intl. Inc trades at $297.28 (market cap $14.23B), while ImmunityBio Inc. Common Stock trades at $10.03 (market cap $10.51B). The key difference: Charles River Laboratories Intl. Inc is the larger of the two by market cap, and ImmunityBio Inc. Common Stock is more actively traded (10,445,785 versus 1,176,885). Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and ImmunityBio Inc. Common Stock for 0 Days on average.
| CRL | IBRX | |
|---|---|---|
Market Cap | $14.23B | $10.51B |
Volume | 1,176,885 | 10,445,785 |
Sector | Health | Health |
52-Week High | $310.77 | $11.55 |
52-Week Low | $149.93 | $1.98 |
Typical Hold Time | 33 Days | 0 Days |
Enterprise Value | $17.06B | $10.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.30, down 1.53% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus target. The stock maintains a bullish technical signal with support at $295 and resistance at $306. Recent earnings have consistently beaten expectations, though the company faces profitability challenges with negative net income margins and elevated valuation multiples.
While CRL shows promising growth initiatives including 5-7% revenue targets and $300M savings by 2030, investors face risks from negative profitability, high debt levels, and premium valuations. The stock's near-term catalyst will be Q3 2026 earnings against $2.97 EPS expectations, with technical positioning suggesting limited downside from current levels.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About ImmunityBio Inc. Common Stock
ImmunityBio develops immune-based therapies for cancer and infectious diseases. Its programs are designed to activate and strengthen the body’s immune response.
Read more on IBRX →
